Last reviewed · How we verify
Litapiprant Tablet — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
Litapiprant Tablet (Litapiprant Tablet) — Sunshine Lake Pharma Co., Ltd..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Litapiprant Tablet TARGET | Litapiprant Tablet | Sunshine Lake Pharma Co., Ltd. | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Litapiprant Tablet CI watch — RSS
- Litapiprant Tablet CI watch — Atom
- Litapiprant Tablet CI watch — JSON
- Litapiprant Tablet alone — RSS
Cite this brief
Drug Landscape (2026). Litapiprant Tablet — Competitive Intelligence Brief. https://druglandscape.com/ci/litapiprant-tablet. Accessed 2026-05-14.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab